Abstracts tagged "Scleroderma"

Abstract Number: 2593 • ACR Convergence 2023
FT011 for the Treatment of Systemic Sclerosis. Results from a Phase II Study
Christopher Denton¹, Wendy Stevens², Nicole Kruger³, Michelle Papadimitriou⁴, Fay Khong⁴, Michelle Bradney³, Darren Kelly⁴ and Robert Lafyatis⁵, ¹University College London, London, United Kingdom, ²Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, ³Certa Therapeutics, Melbourne, Australia, ⁴Certa Therapeutics and Melbourne University, Melbourne, Australia, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by vascular damage, inflammation, and fibrosis of the skin and organs, with no approved disease modifying…
Abstract Number: 0609 • ACR Convergence 2023
Mortality After Autologous Hematopoietic Stem Cell Transplant for Autoimmune Disease: Do Scleroderma Patients Fare Worse?
Marina Birck¹, Autumn Neville¹, Jan Storek², Harry Atkins³, Marie Hudson⁴, Ines Colmegna⁵, Jessie R. Lavoie⁶, Jun Gao⁷ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Health Canada, Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Ottawa, ON, Canada, ⁷Health Canada, Centre for Regulatory Excellence, Statistics and Trials, Biologic and Radiopharmaceutical Drugs Directorate, Ottawa, ON, Canada
Background/Purpose: Autologous hematopoietic stem cell transplantation (HSCT) has benefitted some patients with autoimmune disease (AD) but is associated with toxicity and treatment-related mortality. Autologous HSCT…
Abstract Number: 0650 • ACR Convergence 2023
Understanding the Employment Landscape in People with Systemic Sclerosis
Hila Jazayeri¹, Zareen Ahmad¹, Monique Gignac² and Sindhu Johnson³, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Work & Health, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a systemic rheumatic disease that restricts participation in various life roles, including in the workplace. Our objectives were to identify…
Abstract Number: 0952 • ACR Convergence 2023
Unraveling the Role of MiR-181 in Skin Fibrosis Pathogenesis by Targeting NUDT21
Tingting Mills¹, Minghua Wu², Hydia Puente³, Jerry Alonso⁴, Julio charles⁴, Maureen Mayes⁴ and Shervin Assassi⁵, ¹Biochemistry Department, University of Texas McGovern Medical School, Houston, TX, ²Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ³UTHealth-Houston, Houston, TX, ⁴Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁵University of Texas McGovern Medical School at Houston, Houston, TX
Background/Purpose: Nudix Hydrolase 21 (NUDT21, also known as CFIm25) is a master regulator of alternative polyadenylation. Previous studies have revealed that NUDT21 is significantly decreased…
Abstract Number: 1532 • ACR Convergence 2023
Safety and Microvascular Effects of Long-term Treatment with Aminaphtone in Systemic Sclerosis Patients: A Retrospective Analysis
Alberto Sulli¹, Rosanna Campitiello¹, Emanuele Gotelli¹, Andrea Cere¹, Elvis Hysa², Tamara Vojinovic², Carlotta Schenone¹, Carmen Pizzorni¹, Sabrina Paolino¹, Elisa Alessandri¹, Vanessa Smith³ and Maurizio Cutolo⁴, ¹Laboratory of Experimental Rheumatology and Academic Division of Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy, ³Ghent University Hospital, Gent, Belgium, ⁴Laboratory of Experimental Rheumatology, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genova, Italy
Background/Purpose: The progressive endothelial damage is one of the hallmarks of systemic sclerosis (SSc), an autoimmune connective tissue disease characterized by organ fibrotic involvement. Aminaphtone…
Abstract Number: 2594 • ACR Convergence 2023
Trajectories of Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Oliver Distler¹, Madelon Vonk², Arata Azuma³, Maureen Mayes⁴, Dinesh Khanna⁵, Kristin B Highland⁶, Gerrit Toenges⁷, Margarida Alves⁸ and Yannick Allanore⁹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan, and Meisei Hospital, Saitama, Japan, ⁴Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁵University of Michigan, Ann Arbor, MI, ⁶Cleveland Clinic, Cleveland, OH, ⁷Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France
Background/Purpose: The SENSCIS trial enrolled patients with SSc-ILD without a requirement for them to have evidence of recent progression. During the trial, nintedanib reduced the…
Abstract Number: 0610 • ACR Convergence 2023
Nailfold Capillaroscopy for Prediction of Novel Severe Organ Involvement in Systemic Sclerosis
Cristiana Sieiro Santos¹, Rúben Rego Salgueiro², Clara Moriano Morales³, Carolina Álvarez Castro³ and Elvira Díez Álvarez³, ¹Complejo Asistencial Universitario de León, León, Spain, ²ULS Guarda, Guarda, Portugal, ³CAULE, León, Spain
Background/Purpose: Nailfold capillaroscopy (NFC) has been suggested as a potential biomarker of disease severity in systemic sclerosis (SSc). Several studies report the association between capillary…
Abstract Number: 0652 • ACR Convergence 2023
Ethnic Variations in Systemic Sclerosis Associated Interstitial Lung Disease
Patrick Donio¹, Wesley Fidler², Juan Pablo Diaz-Martinez³, Elvira Bangert⁴, Zareen Ahmad⁵, Medha Soowamber⁶ and Sindhu Johnson⁷, ¹Thunder Bay Regional Health Sciences Centre, Northern Ontario School of Medicine University, Queen's University, Thunder Bay, ON, Canada, ²Northern Ontario School of Medicine, Thunder Bay, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Scleroderma Program, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁶Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Woodbridge, ON, Canada, ⁷Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a multisystem fibrosing autoimmune disease with a high mortality rate. Ethnicity can influence prevalence and disease characteristics in SSc. Less…
Abstract Number: 0954 • ACR Convergence 2023
Non-canonical WNTA Promotes Cytoskeletal Rearrangement and Integrin Alpha V Clustering via JNK and ROCK to Control the Activation of Latent TGFβ
Thuong Trinh-Minh¹, Chih-Wei Chen², Cuong Tran Manh¹, yi-nan Li¹, Honglin Zhu³, Debomita Chakraborty⁴, Yun Zhang¹, Simon Rauber⁵, Clara Dees⁵, Christina Bergmann⁶, Alexander Kreuter⁷, Christiane Reuter⁸, Florian Groeber-Becker⁸, Beate Eckes⁹, Oliver Distler¹⁰, Andreas Ramming¹¹, Georg Schett¹² and Joerg Distler¹, ¹Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ²3 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ³3 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. 5 Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China, ⁴3 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵3 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁶Department Internal Medicine, University Hospital Erlangen, Germany, Erlangen, Germany, ⁷Clinic for Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Clinic, Oberhausen, Germany, ⁸Translational Center for Regenerative Therapies, Fraunhofer Institute for Silicate Research (ISC) Würzburg, Würzburg, Germany, ⁹Translational Matrix Biology, University of Cologne, Cologne, Germany. 9 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Köln, Germany, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ¹²Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder with vasculopathy, inflammation, and fibrosis of the skin and organs. Fibrosis is caused by the abnormal…
Abstract Number: 1621 • ACR Convergence 2023
Maxillofacial MRI Augments Detection of Non-CNS Abnormalities in Pediatric Craniofacial Scleroderma
Daniel Glaser¹, Amy Metry², Elena DeRosas², Subramanian Subramanian² and Kathryn Torok³, ¹Yale University School of Medicine, New Haven, CT, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Craniofacial scleroderma is a rare subtype of linear scleroderma affecting the head and neck. Up to 40% of patients experience extracutaneous manifestations (ECMs), but…
Abstract Number: PP16 • ACR Convergence 2023
Peer Health Coaches Help Scleroderma Patients Cope with Isolation
Mary Alore¹, Yen Chen² and Susan Murphy³, ¹Troy, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Plymouth, MI
Background/Purpose: In 2011, I felt extremely isolated with my new diagnosis of diffuse systemic sclerosis and sought support online and in support groups. In addition…
Abstract Number: 0614 • ACR Convergence 2023
Self-Reported Sexual Dysfunction and Perceptions of Rheumatologist Engagement on This Issue in Patients with Systemic Sclerosis
Liza Morales¹, Robert Spiera², Jessica Gordon¹, Deanna Jannat-Khah¹ and Kimberly Lakin¹, ¹Hospital for Special Surgery, New York, NY, ²Hosptial for Special Surgery, New York, NY
Background/Purpose: Few studies have investigated the prevalence and risk factors of sexual dysfunction among individuals with systemic sclerosis (SSc). The purpose of this study is…
Abstract Number: 0655 • ACR Convergence 2023
A Novel Association Between Lipodermatosclerosis and Key Vascular Outcomes in Systemic Sclerosis
Srijana Davuluri¹, Puneet Kapoor², Swarna Nandyala², David Fiorentino³, Julia Simard⁴ and Lorinda Chung⁵, ¹Stanford University- School of Medicine, Sunnyvale, CA, ²Stanford University- School of Medicine, Palo Alto, CA, ³Department of Dermatology, Stanford University, Redwood City, CA, ⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ⁵Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA
Background/Purpose: Lipodermatosclerosis (LDS) is a progressive manifestation of chronic venous insufficiency characterized by distinctive lower extremity changes, including an "inverted champagne bottle" appearance, skin hyperpigmentation,…
Abstract Number: 0955 • ACR Convergence 2023
GRB2 Serves as a Viable Target Against Skin Fibrosis in Systemic Sclerosis by Regulating Endothelial Cell Apoptosis
Yan Huang, Han Zhao, Xiangguang Shi, Jing Liu, Jui-Ming Lin, Qianqian Ma, Shuai Jiang, Weilin Pu, Yanyun Ma, Jianlan Liu, Wenyu Wu, Jiucun Wang and Qingmei Liu, Shanghai, Shanghai, China
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by vascular and immune system dysfunction, along with tissue fibrosis. Vascular damage has been recognized as…
Abstract Number: 1661 • ACR Convergence 2023
Spatial Transcriptional Alterations in the Cellular Landscape of Pediatric Scleroderma Skin
Kathryn Torok¹, Ying-Ju Lai², Zhongli Xu³, Anwesha Sanyal³, Giffin Werner³, Theresa Hutchins³, Claire Cheng³ and Wei Chen³, ¹University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittbsurgh, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Recent single-cell RNA sequencing (scRNA seq) data has been generated across several tissues in autoimmune diseases, helping to understand the cellular and molecular underpinnings…

« Previous Page
1
…
8
9
10
11
12
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.